Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Giniwa
- Development stage
- Unknown
- Lead developer
- Zinereo Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Giniwa is a line of pharmaceutical-grade probiotic supplements developed by Zinereo Pharma, a subsidiary of the Zendal Group, specifically formulated for women's intimate and maternal health. The product range includes Giniwa V (vaginal health), Giniwa U (urinary tract health), and Giniwa M (maternal health). These oral supplements typically combine specific Lactobacillus strains, such as Lactobacillus acidophilus, Lactobacillus plantarum, and Lactobacillus crispatus, with natural ingredients like propolis, hibiscus extract, and vitamin A. They work by modulating the vaginal and urinary microbiomes through the gut-vagina axis, aiming to prevent recurrent conditions such as bacterial vaginosis and vulvovaginal candidiasis. Marketed as 100% natural and gluten-free, Giniwa products are designed for daily oral administration and emphasize clinical validation and pharmaceutical-quality standards.
- Brand names
- GiniwaGiniwa VGiniwa UGiniwa M
Beyond the preview
Go deeper on Giniwa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Giniwa.